PERSONALIZED MEDICINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In February 2023, Roche, a multinational healthcare company, announced that it has expanded its collaboration with Janssen Biotech Inc., a biotechnology company, to develop companion diagnostics for targeted medicines, thereby enhancing its research and innovation efforts. The new, expanded partnership allows Roche and Janssen to engage in the personalized healthcare area with a variety of companion diagnostics technologies including immunohistochemistry (IHC), digital pathology, next generation sequencing, polymerase chain reaction, and immunoassays.
• In December 2021, Biogen Inc., a biotechnology company, and TheraPanacea, a medical technology company, announced a collaboration focused on numerous therapeutic areas in neuroscience, expanding on the companies' existing relationship. The collaboration intends to develop breakthrough machine learning and Artificial Intelligence technologies for personalized and earlier treatment in neurology.
• In June 2020, Infosys, a global leader in next-generation digital services and consulting, announced the launch of a brand-new personalized medicine solution for pharmaceutical companies. The solution uses SAP S/4HANA, the SAP C/4HANA suite, the SAP Analytics Cloud solution, and the SCI platform to generate intelligent insights, allowing pharmaceutical companies to address important business and regulatory requirements while providing personalized patient experiences.
• In May 2020, Regeneron Pharmaceuticals, Inc., a biotechnology company, and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus announced a large-scale research collaboration to advance the field of human genetics and personalized medicine by sharing 450,000 DNA samples and corresponding health records from de-identified, consented patient participants in the vast UCHealth system.